血清CYFRA21-1在晚期NSCLC疗效监测中的应用价值  

The application significance of serum CYFRA21-1 change in therapeutic efficacy monitoring of advanced stage NSCLC

作　　者：张国明[1] 马小波[1] 胡礼仪[1] 臧家兰[1] 张高明[1] 徐庆雷[1] 

机构地区：[1]江苏省沭阳县人民医院,江苏宿迁223600

出　　处：《检验医学》2013年第2期124-127,共4页Laboratory Medicine

摘　　要：目的探讨晚期非小细胞肺癌(NSCLC)化疗前、后血清细胞角蛋白19片段(CYFRA21-1)变化在疗效监测中的价值。方法用化学发光免疫分析法对66例晚期NSCLC患者化疗前、后和30名健康对照者血清CYFRA21-1含量进行测定,分析不同疗效患者血清CYFRA21-1含量变化差异。结果在进行一线药物化疗前,NSCLC患者血清CYFRA21-1水平明显高于健康对照组(P<0.05),肺鳞癌组患者水平高于肺腺癌组(P<0.05);一线化疗后,缓解组较化疗前CYFRA21-1水平明显下降(P<0.05),无效组和进展组明显高于治疗前(P<0.05)。结论血清CYFRA21-1在监测肺癌化疗患者病情、判断化疗效果中具有确切的价值。Objective To investigate the significance of serum cytokeratin 19 fragment 21-1（CYFRA21-1） changes before and after chemotherapy in monitoring the therapeutic efficacy of advanced stage non small cell lung cancer（NSCLC）. Methods The serum CYFRA21-1 levels of 66 patients with advanced stage NSCLC before and after chemotherapy and 30 healthy controls were measured by chemiluminescence immunoassay,and the change differences of serum CYFRA21-1 in the patients with different therapeutic efficacy were analyzed. Results Compared to those in the controls,serum CYFRA21-1 levels were significantly higher than those in patients before the first-line chemotherapy（P〈0.05）. Furthermore,the serum CYFRA21-1 levels in patients with squamous cell lung carcinoma were higher than those with pulmonary adenocarcinoma（P〈0.05）. Compared to those before chemotherapy,serum CYFRA21-1 levels significantly decreased in release group after the first-line chemotherapy（P〈0.05）. However,compared to those before chemotherapy,serum CYFRA21-1 levels significantly decreased in invalid group and progress group（P〈0.05）. Conclusions Serum CYFRA21-1 is exactly valuable in monitoring the pathogenetic condition and judging the chemotherapy efficacy of the patients with lung cancer.

关 键 词：细胞角蛋白19片段 肺癌 化疗 预测 监测 

分 类 号：R446.62[医药卫生—诊断学]